bit.bio announces CRISPR screening service and appoints Chief Technology Officer
The service supports a broad range of applications, including drug target identification and validation, pathway analysis, mechanistic studies and disease modelling
Credit: Gorodenkoff-shutterstock
The ioScreen platform enables pharmaceutical, biotechnology and in silico companies to access industrial-scale CRISPR screening in human stem cell-derived models without building specialist in-house capabilities
Register for FREE to keep reading
Join 12,000+ scientists, engineers, and IT professionals driving innovation through informatics, HPC, and simulation with:
- Insights into HPC, AI, lab informatics & data
- Curated content for life sciences, engineering & academia
- Access to Breakthroughs: real-world computing success
- Free reports & panels, including the Lab Informatics Guide
- White Papers & software updates for smarter research
Sign up now
Already a member? Log in here
Your data is protected under our privacy policy.
